[TaiCang Biotechnology] The Company's Q1 2026 Consolidated Financial Report Approved by the Board of Directors

1. Date of resolution by the board of directors or approval by the board of directors: 2026/05/12 2. Date approved by the audit committee: 2026/05/12 3. Reporting period for financial report or annual self-declared financial information Start and end dates (YYYY/MM/DD~YYYY/MM/DD): 2026/01/01~2026/03/31 4. Accumulated operating revenue from Jan 1 to end of period (NT$ thousands): 308,435 5. Accumulated operating gross profit (loss) from Jan 1 to end of period (NT$ thousands): 64,956 6. Accumulated operating income (loss) from Jan 1 to end of period (NT$ thousands): (207,240) 7. Accumulated net profit (loss) before tax from Jan 1 to end of period (NT$ thousands): (141,836) 8. Accumulated net profit (loss) for the current period from Jan 1 to end of period (NT$ thousands): (142,242) 9. Accumulated net profit (loss) attributable to owners of the parent from Jan 1 to end of period (NT$ thousands): (142,242) 10. Accumulated basic earnings (loss) per share from Jan 1 to end of period (NT$): (0.47) 11. Total assets at end of period (NT$ thousands): 10,619,357 12. Total liabilities at end of period (NT$ thousands): 2,413,133 13. Equity attributable to owners of the parent at end of period (NT$ thousands): 8,206,224 14. Other matters that should be specified: None